Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2022 and 2023.
-
Annual account missing NBB
Fiscal year 2024 was expected before 31 July 2025 and has not been filed.
Financials
Financial year 2023
PROTEA BIOPHARMA NV from Asse, company number BE0820421545, closed financial year 2023 with a result of € -44,940 after tax. For that financial year PROTEA BIOPHARMA NV recorded a gross margin of € -41,839 and equity of € -999,054. Compared with financial year 2022, the result moved from € -244,094 to € -44,940. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2024.
€ -999,054
▼ € 44,940 vs 2022
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -44,940
▲ 82 % less loss than in 2022
Profit after tax over the fiscal year.
€ 3,072
▼ 17% vs 2022
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.2 million.
People and assets in 2023
€ 295
▼ 41% vs 2022
Book value of vehicles, furniture and equipment.
Debts at end 2023
€ 2.2 million
▲ 2% vs 2022
Loans from banks and other lenders, long and short.
€ 19,204
▼ 57% vs 2022
Supplier invoices still open on the last day of the fiscal year.
€ 34,249
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | Change 2022 → 2023 | |
|---|---|---|---|---|
| Gross margin | € -48,595 | € -173,200 | € -41,839 | ▲ € 131,360 |
| Profit after taxes | € -142,885 | € -244,094 | € -44,940 | ▲ € 199,154 |
| Equity | € -710,020 | € -954,114 | € -999,054 | ▼ € 44,940 |
| Total debts | € 2,037,654 | € 2,237,865 | € 2,298,999 | ▲ 3% |
| Cash | € 874 | € 3,701 | € 3,072 | ▼ 17% |
| Retained profit | € -880,020 | € -1,124,114 | € -1,169,054 | ▼ € 44,940 |
| Bank debt | € 2,011,671 | € 2,191,671 | € 2,243,671 | ▲ 2% |
| Balance sheet total | € 1,327,634 | € 1,283,752 | € 1,299,945 | ▲ 1% |
Key figures of PROTEA BIOPHARMA NV, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.
What happened to PROTEA BIOPHARMA NV?
What happened at PROTEA BIOPHARMA NV in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jean-Paul Deslypere stepped down as director. NBB
- Carine Herbots stepped down as director. NBB
- New annual accounts for financial year 2023: loss of € 44,940. filed late Source: NBB ↗
- Jan Cabri stepped down as director. NBB
- Carine Herbots became a director. NBB
- Jean-Paul Deslypere became a director. NBB
- Jan Cabri became a director. NBB
- New establishment in Brussel. KBO
In short
From € 142,885 loss in 2021 to € 44,940 loss in 2023.
A new publication or filing at PROTEA BIOPHARMA NV? We notify you, reason included.
Follow PROTEA BIOPHARMA NVDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NV R.E.D. LABORATORIES comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PROTEA BIOPHARMA NVThe shares are held by NV R.E.D. LABORATORIES (100%). It owns 100% of KALIDA BV itself.
Directors
According to the 2023 annual accounts
Carine Herbots
Director
since 2024 · until 2025
Jan Cabri
Director
since 2021 · until 2024
since 2022 · until 2028
Shareholders
Participations
KALIDA BV
100%
Establishments
Establishment units
Physical locations of this company
Huinegem 42 box B
1730 Asse
de Tyraslaan 111
1120 Brussel
Active since 10 November 2009
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0820.421.545
- VAT number
- BE 0820.421.545
- Registered office
- Huinegem 42 bus B, 1730 Asse
- Names & denominations
- PROTEA BIOPHARMA NV
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 November 2009
- Peppol
- Active · Active since 30 Dec 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten